IN184589B - - Google Patents

Info

Publication number
IN184589B
IN184589B IN1756CA1997A IN184589B IN 184589 B IN184589 B IN 184589B IN 1756CA1997 A IN1756CA1997 A IN 1756CA1997A IN 184589 B IN184589 B IN 184589B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Victoria Marie Knepp
Steven Joseph Prestrelski
Jessica Gruber Smith
Manley Tin Fah Huang
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Priority to IN44CA2000 priority Critical patent/IN188568B/en
Publication of IN184589B publication Critical patent/IN184589B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN1756CA1997 1996-10-16 1997-09-23 IN184589B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN44CA2000 IN188568B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1996-10-16 2000-01-28

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2816796P 1996-10-16 1996-10-16
US5292097P 1997-07-15 1997-07-15

Publications (1)

Publication Number Publication Date
IN184589B true IN184589B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2000-09-09

Family

ID=26703379

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1756CA1997 IN184589B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1996-10-16 1997-09-23

Country Status (10)

Country Link
US (3) US6264990B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0939655B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2002513390A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR008673A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE218886T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU4821197A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2264776C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69713378T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN184589B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1998016250A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN184589B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1996-10-16 2000-09-09 Alza Corp
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
DE19940748A1 (de) * 1999-08-27 2001-03-01 Hugo Seinfeld Arzneimittel enthaltend xenogene Oligo- oder/und Polyribonukleotide
WO2001037804A2 (en) * 1999-11-22 2001-05-31 Universal Preservation Technologies, Inc. Preservation and formulation of bioactive materials
US7456009B2 (en) * 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
AU4346101A (en) * 2000-03-07 2001-09-17 Merck & Co., Inc. Adenovirus formulations
US7153472B1 (en) 2000-11-22 2006-12-26 Quadrant Drug Delivery Limited Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
US6827250B2 (en) * 2001-06-28 2004-12-07 Microchips, Inc. Methods for hermetically sealing microchip reservoir devices
AU2002353013A1 (en) 2001-12-03 2003-06-17 Massachusetts Institute Of Technology Microscale lyophilization and drying methods for the stabilization of molecules
EP1534213B1 (en) * 2002-03-13 2013-04-24 Sköld, Thomas Water-based delivery systems
DE60336727D1 (de) * 2002-08-16 2011-05-26 Microchips Inc Vorrichtung mit kontrollierter abgabe und verfahren
US7497855B2 (en) * 2002-09-04 2009-03-03 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
MXPA05003222A (es) * 2002-09-27 2005-07-26 Powderject Res Ltd Particulas revestidas con acido nucleico.
WO2004033034A1 (en) 2002-10-04 2004-04-22 Microchips, Inc. Medical device for neural stimulation and controlled drug delivery
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP1589901A4 (en) * 2002-12-20 2006-08-09 Generipharm Inc INTRACUTANEOUS INJECTION
US8084424B2 (en) * 2003-04-09 2011-12-27 University Of Utah Research Foundation Compositions and methods related to erythropoietin
JP4734236B2 (ja) * 2003-04-25 2011-07-27 ボストン サイエンティフィック サイムド，インコーポレイテッド 固形型の薬物の貯蔵及び制御された放出のための装置及びその製造方法
US7892205B2 (en) 2003-06-06 2011-02-22 Boston Scientific Scimed, Inc. Device and method for delivering micronized therapeutic agents in the body
AU2004285603A1 (en) * 2003-11-03 2005-05-12 Microchips, Inc. Medical device for sensing glucose
WO2006085908A2 (en) * 2004-06-01 2006-08-17 Microchips, Inc. Devices and methods for measuring and enhancing drug or analyte transport to/from medical implant
WO2006015299A2 (en) * 2004-07-30 2006-02-09 Microchips, Inc. Multi-reservoir device for transdermal drug delivery and sensing
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US20060029551A1 (en) * 2004-08-05 2006-02-09 Kui Liu Stable particle formulations of erythropoietin receptor agonists
WO2006026768A1 (en) * 2004-09-01 2006-03-09 Microchips, Inc. Multi-cap reservoir devices for controlled release or exposure of reservoir contents
WO2006031500A2 (en) * 2004-09-10 2006-03-23 Becton, Dickinson And Company Reconstituting infusion device
US7488316B2 (en) 2005-01-25 2009-02-10 Microchips, Inc. Control of drug release by transient modification of local microenvironments
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
BRPI0620268B8 (pt) * 2005-12-22 2021-05-25 Oakwood Laboratories LLC composição eficaz como sistema de fornecimento para liberação controlada, seu uso, seu método de fabricação, e método para proteger um agente biologicamente ativo
AU2007266475B2 (en) 2006-05-30 2009-12-03 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
DK2359808T3 (da) 2006-08-09 2013-08-05 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelaggregater
ES2617063T3 (es) * 2007-03-30 2017-06-15 Xisle Pharma Ventures Trust Composición de vesículas lipídicas bifásicas y método para tratar la displasia de cuello uterino por suministro intravaginal
NZ580447A (en) 2007-04-23 2011-06-30 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
JP5658031B2 (ja) 2007-06-22 2015-01-21 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 薄膜凍結による安定したサブミクロンのペプチド又はタンパク質粒子の形成
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
WO2010056657A2 (en) 2008-11-16 2010-05-20 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
US9283184B2 (en) * 2008-11-24 2016-03-15 Massachusetts Institute Of Technology Methods and compositions for localized agent delivery
WO2011037623A1 (en) 2009-09-28 2011-03-31 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
ES2659079T3 (es) * 2010-03-09 2018-03-13 Janssen Biotech, Inc. Formulaciones no acuosas en suspensión de viscosidad reducida a concentración elevada
JP5816636B2 (ja) 2010-03-17 2015-11-18 ノバリック ゲーエムベーハー 眼圧上昇の治療のための医薬組成物
US20120046225A1 (en) 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
JP6063877B2 (ja) 2011-03-10 2017-01-18 ゼリス ファーマシューティカルズ インコーポレイテッド ペプチド薬物の非経口注射用の安定な製剤
ES2617968T3 (es) 2011-05-25 2017-06-20 Novaliq Gmbh Composición farmacéutica para la administración a uñas
ES2808051T3 (es) 2011-05-25 2021-02-25 Novaliq Gmbh Composición farmacéutica tópica a base de alcanos semifluorados
WO2013067022A1 (en) 2011-10-31 2013-05-10 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes
KR101989648B1 (ko) 2012-01-23 2019-06-14 노바리크 게엠베하 부분불소화 알칸에 기초한 안정화된 단백질 조성물
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
ES2965828T3 (es) 2012-09-12 2024-04-17 Novaliq Gmbh Composiciones de alcano semifluorado
CN113694048B (zh) 2012-09-12 2023-03-24 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
JP6542128B2 (ja) 2013-01-11 2019-07-10 コルセア ファーマ インコーポレイテッド トレプロスチニルのプロドラッグ
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
CA2899089C (en) * 2013-03-15 2021-10-26 Biogen Ma Inc. Factor ix polypeptide formulations
WO2015011199A1 (en) 2013-07-23 2015-01-29 Novaliq Gmbh Stabilized antibody compositions
US10159646B2 (en) 2013-08-12 2018-12-25 Altum-Avro Pharma Partnership Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US8986732B2 (en) 2013-08-12 2015-03-24 Helix Biopharma Corporation Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
ES2904276T3 (es) 2013-09-27 2022-04-04 Massachusetts Inst Technology Nanoestructuras de proteínas biológicamente activas sin vehículo
SG10201808249VA (en) 2014-03-24 2018-10-30 Bioverativ Therapeutics Inc Lyophilized factor ix formulations
EP3828160A1 (en) 2014-07-16 2021-06-02 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
JP6982495B2 (ja) 2014-08-06 2021-12-17 ゼリス ファーマシューティカルズ インコーポレイテッド ペーストの皮内および／または皮下注射のためのシリンジ、キット、および方法
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CA2962768C (en) 2014-10-01 2023-10-10 Alyssa M. Larson Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
EP4278996A3 (en) 2015-06-03 2024-01-24 i2o Therapeutics, Inc. Implant placement systems
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
EP3334417A4 (en) 2015-08-12 2019-07-17 Massachusetts Institute of Technology CELL SURFACE COUPLING OF NANOPARTICLES
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
PT3355990T (pt) 2015-09-30 2019-09-11 Novaliq Gmbh Compostos semifluorados e as suas composições
EP3356313B1 (en) 2015-09-30 2020-05-06 Novaliq GmbH 2-perfluorohexyl octane for ophthalmic administration
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CA3029813A1 (en) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
CA3027767C (en) 2016-06-23 2024-01-30 Novaliq Gmbh Topical administration method
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
KR20190057338A (ko) 2016-09-23 2019-05-28 노바리크 게엠베하 시클로스포린을 포함하는 안과 조성물
CA3049034A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
EP3612228B1 (en) 2017-04-21 2023-08-23 Dermaliq Therapeutics, Inc. Iodine compositions
WO2018206656A1 (en) 2017-05-12 2018-11-15 Novaliq Gmbh Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
CA3063324A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
US11020403B2 (en) 2017-06-02 2021-06-01 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
US11524033B2 (en) 2017-09-05 2022-12-13 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
MX2020003534A (es) 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
CN119909046A (zh) 2017-10-04 2025-05-02 诺瓦利克有限责任公司 包含f6h8的眼用组合物
US11576893B2 (en) 2018-03-02 2023-02-14 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
CN112153970A (zh) 2018-04-27 2020-12-29 诺瓦利克有限责任公司 用于治疗青光眼的包含他氟前列素的眼用组合物
WO2019217637A1 (en) * 2018-05-09 2019-11-14 Biomatrica, Inc. Stabilization of proteins in biological samples
EP3863658B1 (en) 2018-10-12 2024-02-14 Novaliq GmbH Ophthalmic composition for treatment of dry eye disease
WO2020163446A1 (en) 2019-02-05 2020-08-13 Lindy Biosciences, Inc. Isolated cell culture components and methods for isolating the same from liquid cell culture medium
WO2020165132A1 (en) 2019-02-13 2020-08-20 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
CN115397480A (zh) 2019-12-06 2022-11-25 广州倍绣生物技术有限公司 可流动纤维蛋白原凝血酶糊剂
WO2022109294A2 (en) * 2020-11-20 2022-05-27 Team Medical Llc Rna stabilization
WO2023044455A2 (en) * 2021-09-16 2023-03-23 Team Medical Llc Rna stabilization

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2342073A1 (fr) 1976-02-27 1977-09-23 Merieux Inst Nouveau vaccin antivariolique sous forme de pate et son dispositif d'application
EP0177342A3 (en) 1984-10-04 1987-12-02 Genentech, Inc. Oral formulation of therapeutic proteins
IT8922398A0 (it) 1989-11-16 1989-11-16 Phidea Spa Composizioni farmaceutiche ad elevato assorbimento e stabilita', comprendente una calcitonina come sostanza attiva.
US5518731A (en) * 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
WO1993025673A1 (en) 1992-06-04 1993-12-23 The Regents Of The University Of California In vivo gene therapy with intron-free sequence of interest
AU5018693A (en) 1992-09-21 1994-04-12 Upjohn Company, The Sustained-release protein formulations
US5480914A (en) 1994-05-06 1996-01-02 Allergan, Inc. Nonaqueous thixotropic drug delivery suspensions and methods of their use
WO1996027393A1 (en) 1995-03-07 1996-09-12 University Of Pittsburgh A dry powder formulation for gene therapy
US5811406A (en) 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
IN184589B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1996-10-16 2000-09-09 Alza Corp

Also Published As

Publication number Publication date
WO1998016250A1 (en) 1998-04-23
EP0939655A1 (en) 1999-09-08
US6730328B2 (en) 2004-05-04
ATE218886T1 (de) 2002-06-15
AU4821197A (en) 1998-05-11
EP0939655B1 (en) 2002-06-12
CA2264776A1 (en) 1998-04-23
US6264990B1 (en) 2001-07-24
US20010038859A1 (en) 2001-11-08
AR008673A1 (es) 2000-02-09
JP2002513390A (ja) 2002-05-08
CA2264776C (en) 2008-11-25
US20040151779A1 (en) 2004-08-05
DE69713378T2 (de) 2003-01-30
DE69713378D1 (de) 2002-07-18

Similar Documents

Publication Publication Date Title
AR026661A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BRPI9713914B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN184589B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN192215B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN192434B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ITCA960004A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN185387B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN188292B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ITMI960373A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ITMI960581A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ITMI960703V0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN3045530S (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN3045806S (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN3044349S (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN3044348S (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN3044347S (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN3044346S (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN3044168S (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN3043305S (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN3047494S (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN3042589S (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN3042289S (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN3042193S (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN3040367S (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN3047495S (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)